Table 1.
Waldenström macroglobulinemia incidence (1980–2016) and incidence-based mortality (1990–2016): the SEER-9 registry database.
| Characteristic | Incidence | Incidence-based mortality | ||
|---|---|---|---|---|
| Cases, No. (%) | Rate (95% CI) | Deaths, No. (%) | Rate (95% CI) | |
| Overall | 4,472 (100) | 0.48 (0.47–0.5) | 2,420 (100) | 0.34 (0.32–0.35) |
| Age, years | ||||
| <50 | 365 (8.16) | 0.06 (0.05–0.06) | 136 (5.62) | 0.02 (0.02–0.02) |
| 50–59 | 709 (15.85) | 0.65 (0.60–0.70) | 265 (10.95) | 0.03 (0.03–0.04) |
| 60–69 | 1,129 (25.25) | 1.46 (1.37–1.55) | 519 (21.45) | 0.07 (0.07–0.08) |
| 70–79 | 1,326 (29.65) | 2.67 (2.53–2.82) | 817 (33.76) | 0.12 (0.11–0.13) |
| 80+ | 943 (21.09) | 3.20 (3.00–3.41) | 683 (28.22) | 0.09 (0.09–0.10) |
| Sex | ||||
| Male | 2,598 (58.09) | 0.65 (0.62–0.68) | 1,422 (58.76) | 0.50 (0.47–0.52) |
| Female | 1,874 (41.91) | 0.36 (0.34–0.38) | 998 (41.24) | 0.23 (0.22–0.24) |
| Race# | ||||
| White | 3,936 (88.01) | 0.52 (0.50–0.53) | 2,150 (88.84) | 0.36 (0.34–0.38) |
| Black | 242 (5.41) | 0.29 (0.26–0.33) | 142 (5.87) | 0.24 (0.20–0.28) |
| Other$ | 254 (5.68) | 0.3 (0.26–0.33) | 124 (5.12) | 0.18 (0.15–0.22) |
| Geographical region | ||||
| East | 1,009 (22.56) | 0.48 (0.45–0.51) | 486 (20.08) | 0.30 (0.28–0.33) |
| Northern plains | 1,323 (29.58) | 0.49 (0.47–0.52) | 778 (32.15) | 0.37 (0.35–0.40) |
| Pacific coast | 1,762 (39.4) | 0.54 (0.51–0.56) | 943 (38.97) | 0.37 (0.34–0.39) |
| Southwest | 378 (8.45) | 0.31 (0.28–0.35) | 213 (8.8) | 0.23 (0.20–0.26) |
| Primary site of involvement* | ||||
| Bone marrow | 3,044 (68.07) | 0.33 (0.32–0.34) | 1,601 (66.16) | 0.22 (0.21–0.23) |
| Extramedullary disease | 1,421 (31.78) | 0.15 (0.14–0.16) | 815 (33.68) | 0.11 (0.11–0.12) |
| Subtype recode | ||||
| Lymphoplasmacytic lymphoma | 1,878 (41.99) | 0.20 (0.19–0.21) | 958 (39.59) | 0.13 (0.12–0.14) |
| Waldenström macroglobulinemia | 2,594 (58.01) | 0.28 (0.27–0.29) | 1,462 (60.41) | 0.20 (0.19–0.21) |
The limited number of patients whose race was unknown was excluded from further evaluation in the incidence and incidence-based mortality (IBM) (n = 40 and n = 4, respectively) analyses. Therefore, the percentages of patients of different races in the incidence and IBM analyses do not add up to 100%.
The limited number of patients whose primary site of involvement was unknown was excluded from further evaluation in the incidence and IBM (n = 7 and n = 4, respectively) analyses. Therefore, the percentages of patients with different primary sites of involvement in the incidence and IBM analyses do not add up to 100%.
The patients whose race was other include American Indian/Alaskan Native and Asian/Pacific Islander.
SEER, Surveillance, Epidemiology, and End Results database.